Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 11/20 | 0.36 |
| ▸ | MMP2 | P08253 | 9/20 | 0.36 |
| ▸ | MMP1 | P03956 | 9/20 | 0.36 |
| ▸ | MMP9 | P14780 | 3/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | MMP7 | P09237 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | RRM1 | P23921 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21844018 | 0.76 | FPR2 (0.34) | MMP3MMP2MMP1MMP9MMP7 | |
| SCHEMBL12631594 | 0.75 | KDM4C (0.42) | KDM4CUSP2TSHRMMP3MMP2 | |
| SCHEMBL26479785 | 0.74 | RRM1 (0.42) | MMP3MMP1DPP7RRM1 | |
| SCHEMBL25888391 | 0.73 | USP2 (0.40) | KDM4CUSP2TSHRMMP3MMP2 | |
| SCHEMBL12884381 | 0.73 | KDM4C (0.41) | KDM4CUSP2TSHRMMP3MMP2 | |
| SCHEMBL12788693 | 0.72 | KDM4C (0.40) | KDM4CUSP2TSHRMMP3MMP2 | |
| SCHEMBL17664878 | 0.71 | KDM4C (0.39) | KDM4CUSP2TSHRMMP3MMP2 | |
| SCHEMBL14952312 | 0.70 | MMP3 (0.34) | MMP3MMP2MMP1MMP9MMP7 | |
| SCHEMBL10489342 | 0.70 | USP2 (0.44) | KDM4CUSP2TSHRMMP3MMP2 | |
| SCHEMBL19135447 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440626-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440626-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | ABBOTT GMBH & CO. KG (DE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | ABBOTT GMBH & CO. KG (DE) | 2011-04-28 | — | — | US | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20080234205-A1 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234205-A1 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234205-A1 | Antineoplastic peptides | BCL2A1, ETF1, BAK1 | KDM4C 3555/4885USP2 2926/4885TSHR 1709/4885 |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | BCL2A1, CSTB, BAK1 | KDM4C 4015/4885USP2 3104/4885TSHR 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.